RealFeedApp beta

C2N Diagnostics turns Alzheimer's diagnosis into a minimally invasive procedure

C2N Diagnostics' PrecivityAD and PrecivityAD2 tests detect amyloid and tau biomarkers. Japanese regulators approved these blood-based methods for early Alzheimer's diagnosis.

Field
medicine and diagnostics
What they did
C2N Diagnostics developed blood tests that measure specific protein biomarkers to enable early detection of Alzheimer's disease.
Why it matters
This approach offers a minimally invasive alternative to procedures like spinal taps or MRI scans, making diagnosis more accessible for patients.
#alzheimer's#biomarker#diagnosis#japan#precision medicine

Read the original →